| Author (Person) | Mahalatchimy, A. |
|---|---|
| Series Title | European Journal of Health Law |
| Series Details | Vol.18, No.3, June 2011, p305-317 |
| Publication Date | June 2011 |
| ISSN | 0929-0273 |
| Content Type | Journal | Series | Blog |
|
Abstract: The European Union has a public health strategy and will generally ensure in all its policies and activities a “high level of human health protection”. The new Regulation (EC) no 1394/2007 on advanced therapy medicinal products (ATMP), stems from this global policy and aims to harmonise access to the ATMP market. A real will for the harmonisation is clearly expressed in legal texts and enforced in the implementable procedures and requirements. However, several barriers remain. On the one hand, the scope of the ATMP Regulation is limited. On the other hand, Member States benefit from a wide margin of action. |
|
| Source Link | Link to Main Source http://dx.doi.org/10.1163/157180911X574146 |
| Subject Categories | Health |
| Countries / Regions | Europe |
